Clinical trial of Wuling capsules in the treatment of Parkinson's disease with depression
10.13699/j.cnki.1001-6821.2017.11.006
- VernacularTitle:乌灵胶囊治疗帕金森病伴抑郁的临床研究
- Author:
Yan XIE
1
;
Zhi-Yu GAO
;
Xue-Hua WANG
;
Xiao-Jun LI
Author Information
1. 北京大学国际医院
- Keywords:
Wuling capsule;
Parkinson's disease;
depression;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(11):980-982
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of Wuling capsules in the treatment of Parkinson's disease with depression.Methods A total of 86 patients of Parkinson's disease with depression were randomly divided into treatment group and control group with 43 cases per group.Control group was given levodopa and benserazide hydrochloride 250 mg,qd,oral + sertraline hydrochloride 100 mg,qd,oral.Treatment group received Wuling capsule 0.99 g,tid,oral,on the basis of control group.Two groups were treated for 12 weeks.The clinical efficacy,motor function,depressive symptoms,serum biochemical indexes and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates in treatment and control groups were 93.02％ (40/43 cases) and 74.42％ (32/43 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:the unified Parkinson's disease rating scale scores were (17.72 ± 3.24),(22.02±3.44) points;unified Parkinson's disease rating scale scores were (1.17 ± 0.42),(1.90 ± 0.51) points;the Hamilton depression scale (HAMD) scores were (9.72±1.12),(13.27 ±2.14) points;serum cystatin C were (0.80 ±0.11),(0.92 ±0.16) mg · L-1;malondialdehyde were (5.33 ± 0.57),(6.27 ± 0.85) μ mol · L-1;superoxide dismutase were (86.79 ± 10.65),(80.12 ± 8.38) U · mL-1,the differences were statistically significant (P ＜ 0.05).The adverse drug reactions in two groups were nausea,dry mouth,insomnia,lack of appetite and fatigue,the incidences of adverse drug reactions in treatment and control groups were 18.60％ and 13.96％ without significant difference (P ＞ 0.05).Conclusion Wuling capsule has a definitive clinical in the treatment of Parkinson's disease with depression,without increasing the incidence of adverse drug reactions.
